Skip to Content

Losartan

Class: Angiotensin II Receptor Antagonists
VA Class: CV805
Chemical Name: 2-Butyl-4-chloro-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]-methyl]-1H-imidazole-5-methanol monopotassium salt
Molecular Formula: C22H23ClN6O
CAS Number: 124750-99-8
Brands: Cozaar

Medically reviewed by Drugs.com. Last updated on Oct 26, 2020.

Warning

  • May cause fetal and neonatal morbidity and mortality if used during pregnancy. (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

  • If pregnancy is detected, discontinue as soon as possible.

Introduction

Angiotensin II receptor (AT1) antagonist (i.e., angiotensin II receptor blocker, ARB).

Uses for Losartan

Hypertension

Management of hypertension (alone or in combination with other classes of antihypertensive agents, including diuretics).

Angiotensin II receptor antagonists are recommended as one of several preferred agents for the initial management of hypertension according to current evidence-based hypertension guidelines; other preferred options include ACE inhibitors, calcium-channel blockers, and thiazide diuretics. While there may be individual differences with respect to recommendations for initial drug selection and use in specific patient populations, current evidence indicates that these antihypertensive drug classes all generally produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes.

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).

A 2017 ACC/AHA multidisciplinary hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension. (See Table 1.)

Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200

Category

SBP (mm Hg)

DBP (mm Hg)

Normal

<120

and

<80

Elevated

120–129

and

<80

Hypertension, Stage 1

130–139

or

80–89

Hypertension, Stage 2

≥140

or

≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP. However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk. In addition, an SBP goal of <130 mm Hg is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg. These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.

Previous hypertension guidelines generally have based target BP goals on age and comorbidities. Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients compared with those recommended by the 2017 ACC/AHA hypertension guideline.

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the current ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient’s BP treatment goal.

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors. ASCVD risk assessment recommended by ACC/AHA for all adults with hypertension.

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP. Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to angiotensin II receptor antagonists. However, the combination of an ACE inhibitor or an angiotensin II receptor antagonist with a calcium-channel blocker or thiazide diuretic produces similar BP lowering in black patients as in other racial groups.

Angiotensin II receptor antagonists or ACE inhibitors may be particularly useful in hypertensive patients with diabetes mellitus or CKD; angiotensin II receptor antagonists also may be preferred, as an alternative to ACE inhibitors, in hypertensive patients with heart failure or ischemic heart disease and/or post-MI.

Prevention of Cardiovascular Morbidity and Mortality

Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.

Evidence suggests that the benefit associated with such losartan-based antihypertensive therapy does not apply to black patients.

Preliminary evidence suggests that aspirin therapy at baseline in patients receiving losartan may reduce the risk of combined cardiovascular death, stroke, and acute MI compared with aspirin therapy at baseline in patients receiving atenolol.

Diabetic Nephropathy

Management of diabetic nephropathy manifested by elevated Scr and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes mellitus and hypertension.

A recommended agent in the management of patients with diabetes mellitus and persistent albuminuria who have modestly elevated (30–300 mg/24 hours) or higher (>300 mg/24 hours) levels of urinary albumin excretion; slows rate of progression of renal disease in such patients.

Heart Failure

Angiotensin II receptor antagonists have been used in the management of heart failure.

Because of their established benefits, ACE inhibitors have been the preferred drugs for inhibition of the renin-angiotensin-aldosterone (RAA) system in patients with heart failure and reduced left ventricular ejection fraction (LVEF); however, some evidence indicates that therapy with an ACE inhibitor (enalapril) may be less effective than angiotensin receptor-neprilysin inhibitor (ARNI) therapy (e.g., sacubitril/valsartan) in reducing cardiovascular death and heart failure-related hospitalization.

Angiotensin II receptor antagonists may be used as an alternative for those patients in whom an ACE inhibitor or ARNI is inappropriate.

ACCF, AHA, and the Heart Failure Society of America (HFSA) recommend that patients with chronic symptomatic heart failure and reduced LVEF (NYHA class II or III) who are able to tolerate an ACE inhibitor or angiotensin II receptor antagonist be switched to therapy containing an ARNI to further reduce morbidity and mortality.

Losartan Dosage and Administration

General

BP Monitoring and Treatment Goals

  • Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.

  • If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.

  • If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., calcium-channel blocker, thiazide diuretic). Many patients will require at least 2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved with 2 antihypertensive agents, add a third drug.

Administration

Oral Administration

Administer losartan orally once or twice daily without regard to meals. Administer losartan as extemporaneously prepared oral suspension in patients unable to swallow tablets. Administer losartan in fixed combination with hydrochlorothiazide once daily without regard to meals.

Reconstitution

Preparation of extemporaneous suspension containing losartan potassium 2.5 mg/mL: Add 10 mL of purified water to a 240-mL polyethylene terephthalate (PET) bottle containing ten 50-mg tablets of losartan potassium; shake contents for ≥2 minutes. Allow concentrated suspension to stand for 60 minutes following reconstitution, then shake for an additional minute. Prepare a mixture containing equal parts (by volume) of syrup (Ora-Sweet) and suspending vehicle (Ora-Plus) separately. Dilute the concentrated suspension of losartan potassium with 190 mL of the Ora-Sweet and Ora-Plus mixture; shake the container an additional minute to disperse ingredients. Shake suspension before dispensing each dose.

Dosage

Available as losartan potassium; dosage expressed in terms of the salt.

Pediatric Patients

Hypertension
Oral

Children ≥6 years of age: Initially, 0.7 mg/kg (up to 50 mg) once daily. Dosage may be increased every 2–4 weeks until BP controlled, maximum dosage reached (maximum dosage of 1.4 mg/kg or 100 mg daily), or adverse effects occur. .

Adults

Hypertension
Losartan Therapy
Oral

Manufacturer recommends initial dosage of 50 mg once daily in adults without intravascular volume depletion. In adults with depletion of intravascular volume, the usual initial dosage is 25 mg once daily.

Usual dosage: Manufacturer states 25–100 mg daily, given in 1 dose or 2 divided doses; no additional therapeutic benefit with higher dosages. Some experts state 50–100 mg daily, given in 1 dose or 2 divided doses.

If effectiveness diminishes toward end of dosing interval in patients treated once daily, consider increasing dosage or administering drug in 2 divided doses.

Losartan/Hydrochlorothiazide Fixed-combination Therapy
Oral

Manufacturer states fixed-combination preparation should not be used for initial treatment of hypertension, except in severe hypertension when benefits of achieving prompt BP reduction are considered to outweigh risks of initiating combination therapy.

If BP is not adequately controlled by monotherapy with losartan potassium or hydrochlorothiazide (25 mg daily), if BP is controlled but hypokalemia is problematic at this hydrochlorothiazide dosage, or in those with severe hypertension in whom the potential benefit of achieving prompt BP control outweighs the potential risk of initiating therapy with the commercially available fixed combination, can use the fixed-combination tablets once daily (losartan potassium 50 mg and hydrochlorothiazide 12.5 mg; then losartan potassium 100 mg and hydrochlorothiazide 25 mg, if BP remains uncontrolled after about 3 weeks of therapy [or after 2–4 weeks of therapy in those with severe hypertension]).

If BP is not adequately controlled by monotherapy with losartan potassium 100 mg daily, can switch to fixed-combination tablets once daily (losartan potassium 100 mg and hydrochlorothiazide 12.5 mg; then losartan potassium 100 mg and hydrochlorothiazide 25 mg [administered as 2 tablets of the fixed combination containing 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide, or alternatively, as 1 tablet of the fixed combination containing 100 mg of losartan potassium and 25 mg of hydrochlorothiazide] if BP remains uncontrolled after about 3 weeks of therapy).

Prevention of Cardiovascular Morbidity and Mortality
Oral

Initially, 50 mg once daily. Adjust dosage based on BP response. If indicated, add hydrochlorothiazide 12.5 mg daily and/or increase dosage of losartan to 100 mg once daily. Subsequently, may increase hydrochlorothiazide dosage to 25 mg once daily. Alternatively, administer fixed combination of losartan potassium and hydrochlorothiazide at appropriate dosages.

Diabetic Nephropathy
Oral

Initially, 50 mg once daily. If BP is not adequately controlled, increase dosage to 100 mg once daily.

Heart Failure†
Oral

Initially, 25–50 mg once daily recommended by ACCF and AHA in patients with prior or current symptoms of heart failure and reduced LVEF (ACCF/AHA stage C heart failure).

ACCF and AHA recommend maximum dosage of 50–150 mg once daily in patients with ACCF/AHA stage C heart failure.

Reevaluate BP, renal function, and serum potassium concentrations within 1–2 weeks after initiation of therapy and monitor such parameters closely after dosage changes.

Prescribing Limits

Pediatric Patients

Hypertension
Oral

Maximum 1.4 mg/kg or 100 mg daily.

Adults

Hypertension
Losartan/Hydrochlorothiazide Fixed-combination Therapy
Oral

Maximum 100 mg of losartan potassium and 25 mg of hydrochlorothiazide daily as the fixed combination.

Special Populations

Hepatic Impairment

Manufacturer recommends initial dosage of 25 mg once daily in adults with a history of hepatic impairment.

Use of losartan in fixed combination with hydrochlorothiazide is not recommended in patients with hepatic impairment.

Renal Impairment

No initial dosage adjustments recommended by manufacturer for adults with renal impairment, including those undergoing hemodialysis. Use not recommended in pediatric patients with Clcr <30 mL/minute per 1.73 m2.

Use of losartan in fixed combination with hydrochlorothiazide is not recommended in patients with severe renal impairment.

Geriatric Patients

No initial dosage adjustments necessary.

Volume- and/or Salt-depleted Patients

Correct volume and/or salt depletion prior to initiation of therapy or initiate therapy under close medical supervision using lower initial dosage (25 mg once daily).

Use of losartan in fixed combination with hydrochlorothiazide is not recommended in patients with intravascular volume depletion (e.g., patients receiving diuretics).

Cautions for Losartan

Contraindications

  • Known hypersensitivity to losartan or any ingredient in the formulation.

  • Concomitant therapy with aliskiren in patients with diabetes mellitus. (See Specific Drugs under Interactions.)

Warnings/Precautions

Warnings

Fetal/Neonatal Morbidity and Mortality

Possible reduction in renal function and increase in fetal and neonatal morbidity and mortality when drugs that act on the renin-angiotensin system (e.g., angiotensin II receptor antagonists, ACE inhibitors, aliskiren) are used during the second and third trimesters of pregnancy. (See Boxed Warning.) Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

Discontinue losartan as soon as possible when pregnancy is detected, unless continued use is considered lifesaving. Nearly all women can be transferred successfully to alternative therapy for the remainder of their pregnancy.

Sensitivity Reactions

Anaphylactoid reactions and/or angioedema possible; not recommended in patients with a history of angioedema associated with or unrelated to ACE inhibitor or angiotensin II receptor antagonist therapy.

Other Warnings and Precautions

Hypotension

Possible symptomatic hypotension, particularly in volume- and/or salt-depleted patients (e.g., those treated with diuretics). (See Volume- and/or Salt-Depleted Patients under Dosage and Administration.)

Malignancies

In July 2010, FDA initiated a safety review of angiotensin II receptor antagonists after a published meta-analysis found a modest but statistically significant increase in risk of new cancer occurrence in patients receiving an angiotensin II receptor antagonist compared with control. However, subsequent studies, including a larger meta-analysis conducted by FDA, have not shown such risk. Based on currently available data, FDA has concluded that angiotensin II receptor antagonists do not increase the risk of cancer.

Renal Effects

Possible oliguria, progressive azotemia and, rarely, acute renal failure and/or death in patients with severe heart failure.

Increases in BUN and Scr possible in patients with renal artery stenosis, CKD, or volume depletion.

Consider withholding or discontinuing losartan in patients who develop a clinically important reduction in renal function while receiving losartan.

Effects on Potassium

Hyperkalemia can develop, especially in patients with renal impairment or diabetes mellitus and those receiving agents that can increase serum potassium concentration (e.g., potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes).

Use of Fixed Combinations

When losartan is used in fixed combination with hydrochlorothiazide, consider the cautions, precautions, and contraindications associated with hydrochlorothiazide.

Specific Populations

Pregnancy

Category D.

Can cause fetal and neonatal morbidity and mortality. (See Boxed Warning.) Discontinue as soon as possible when pregnancy is detected. (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

Lactation

Losartan and its active metabolite are distributed into milk in rats; not known whether distributed into human milk. Discontinue nursing or the drug.

Pediatric Use

If oliguria or hypotension occurs in neonates with a history of in utero exposure to losartan, support BP and renal function; exchange transfusions or dialysis may be required. (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

Safety and efficacy not established in children <6 years of age or in pediatric patients with Clcr <30 mL/minute per 1.73 m2.

Geriatric Use

No substantial differences in safety or efficacy of losartan monotherapy relative to younger adults, but increased sensitivity cannot be ruled out.

No apparent overall differences in efficacy with fixed combination containing losartan and hydrochlorothiazide in patients ≥65 years of age compared with younger adults. Adverse effects more frequent in geriatric patients compared with younger patients; select dosage with caution.

Hepatic Impairment

Systemic exposure to losartan and its active metabolite may be increased. (See Absorption: Special Populations, under Pharmacokinetics.) Initial dosage adjustment recommended. (See Hepatic Impairment under Dosage and Administration.)

Use of losartan in fixed combination with hydrochlorothiazide is not recommended in patients with hepatic impairment (tablet dosage exceeds recommended initial dosage).

Renal Impairment

Deterioration of renal function may occur. (See Renal Effects under Cautions.)

Use of losartan in fixed combination with hydrochlorothiazide is not recommended in patients with Clcr <30 mL/minute.

Black Patients

BP reduction may be smaller in black patients than in patients of other races. (See Hypertension under Uses.)

No evidence that the benefits of therapy in reducing the risk of cardiovascular events in hypertensive patients with left ventricular hypertrophy apply to black patients.

Common Adverse Effects

Patients with hypertension: upper respiratory infection, dizziness, nasal congestion, back pain, leg pain, muscle cramp, sinusitis.

Patients with diabetic nephropathy: Urinary tract infection, diarrhea, anemia, asthenia/fatigue, hypoglycemia, chest pain, cough, bronchitis, diabetic vascular disease, influenza-like disease, cataracts, cellulitis, hyperkalemia, hypotension, muscular weakness, sinusitis, gastritis, hypoesthesia, infection, knee pain, and leg pain.

Interactions for Losartan

Formation of active metabolite appears to be mediated by CYP2C9. CYP3A4 apparently contributes to formation of inactive metabolites.

Drugs Affecting Hepatic Microsomal Enzymes

CYP2C9 inhibitors: Possible inhibition of the formation of losartan’s active metabolite.

CYP3A4 inhibitors: Clinically important interactions unlikely (possible increased concentration of losartan, but no effects on formation of active metabolite observed).

Specific Drugs

Drug

Interaction

Comment

ACE inhibitors

Increased risk of renal impairment, hyperkalemia, and hypotension

Generally avoid concomitant use

Monitor BP, renal function, and electrolytes if used concomitantly

Aliskiren

Increased risk of renal impairment, hyperkalemia, and hypotension

Generally avoid concomitant use

Monitor BP, renal function, and electrolytes if used concomitantly

Concomitant use contraindicated in patients with diabetes mellitus

Avoid concomitant use in patients with GFR <60 mL/minute

Angiotensin II receptor antagonists

Increased risk of renal impairment, hyperkalemia, and hypotension

Generally avoid concomitant use

Monitor BP, renal function, and electrolytes if used concomitantly

Cimetidine

Pharmacokinetic interaction unlikely

Digoxin

Pharmacokinetic interaction unlikely

Diuretics, potassium-sparing

Possible hyperkalemia

Monitor serum potassium concentrations

Erythromycin

Clinically important pharmacokinetic interaction unlikely

Fluconazole

Decreased plasma concentrations of losartan’s active metabolite and increased plasma losartan concentrations

Hydrochlorothiazide

Pharmacokinetic interaction unlikely

Additive hypotensive effects; used for therapeutic advantage in hypertension treatment

Ketoconazole

Conversion of losartan to its active metabolite unaffected

Lithium

Lithium excretion may be reduced

Carefully monitor serum lithium concentrations

NSAIAs, including selective cyclooxygenase-2 (COX-2) inhibitors

Possible deterioration of renal function in geriatric, volume-depleted, or renally impaired patients

Possible decreased hypotensive effect

Monitor renal function periodically

Phenobarbital

Pharmacokinetic interaction unlikely

Rifampin

Decreased plasma concentrations of losartan and its active metabolite

Salt substitutes, potassium-containing

Possible hyperkalemia

Monitor serum potassium concentrations

Warfarin

Pharmacokinetic interaction unlikely

Losartan Pharmacokinetics

Absorption

Bioavailability

Well absorbed after oral administration but undergoes substantial first-pass metabolism.

Systemic bioavailability of losartan is about 33%. Bioavailability of the suspension formulation (see Oral Administration under Dosage and Administration) is similar to that of losartan tablets with respect to both the drug and its active metabolite.

Peak plasma concentrations of losartan and its active metabolite attained 1 and 3–4 hours, respectively, following oral administration.

Onset

Antihypertensive effect evident within 1 week, with maximum BP reduction after 3–6 weeks.

Food

Food slows absorption of losartan and decreases its peak plasma concentration but has minimal effect on AUC of losartan or its active metabolite.

Special Populations

In pediatric patients, pharmacokinetics of losartan and its active metabolite generally are similar to historical data in adults.

In patients with hepatic impairment, oral bioavailability is about 2 times higher than in those with normal hepatic function.

In patients with mild to moderate alcoholic cirrhosis, plasma concentration of losartan and its active metabolite were about 5 and 2 times those of healthy individuals, respectively.

In patients with mild (Clcr 50–74 mL/minute) or moderate (Clcr 30–49 mL/minute) renal impairment, plasma concentrations and AUC of losartan and its active metabolite are increased by 50–90%.

Distribution

Extent

Crosses the placenta and is distributed in the fetus in animals.

Crosses the blood-brain barrier poorly, if at all, in animals.

Distributed into milk in rats; not known whether distributed into human milk.

Plasma Protein Binding

Losartan and its active metabolite: >98%.

Elimination

Metabolism

Undergoes biotransformation through CYP2C9 to an active carboxylic acid metabolite that is responsible for most of the drug’s angiotensin II receptor antagonism. CYP3A4 apparently contributes to formation of inactive metabolites.

Elimination Route

Eliminated mainly in urine and feces (via bile).

Half-life

Terminal half-life of losartan and its active metabolite is approximately 2 and 6–9 hours, respectively.

Special Populations

In patients with mild to moderate alcoholic cirrhosis, total plasma clearance of losartan is about 50% lower than in those with normal hepatic function.

In patients with mild or moderate renal impairment, renal clearance of losartan and its active metabolite is decreased by 55–85%. Neither losartan nor its active metabolite is removed by hemodialysis.

Stability

Storage

Oral

Extemporaneous Suspension

2.5-mg/mL preparation of losartan potassium tablets in a mixture of syrup (Ora-Sweet) and suspending vehicle (Ora-Plus) (see Oral Administration under Dosage and Administration): Up to 30 days at 2–8°C.

Tablets

Tight container at 25°C (may be exposed to 15–30°C). Protect from light.

Actions

  • Losartan (prodrug) has little pharmacologic activity until activated in the liver.

  • Losartan’s active metabolite is 10 to 40 times more potent by weight than losartan and appears to be a reversible, noncompetitive inhibitor of the AT1 receptor.

  • Blocks the physiologic actions of angiotensin II, including vasoconstrictor and aldosterone-secreting effects.

  • Does not interfere with response to bradykinins.

  • Does not share the ACE inhibitor common adverse effect of dry cough.

Advice to Patients

  • Risks of use during pregnancy.

  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.

  • Importance of advising patients not to use potassium supplements or salt substitutes containing potassium without consulting their clinician.

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs (including salt substitutes containing potassium).

  • Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Losartan Potassium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

25 mg

Cozaar

Merck

50 mg

Cozaar

Merck

100 mg

Cozaar

Merck

Losartan Potassium Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

50 mg with Hydrochlorothiazide 12.5 mg

Hyzaar

Merck

100 mg with Hydrochlorothiazide 12.5 mg

Hyzaar

Merck

100 mg with Hydrochlorothiazide 25 mg

Hyzaar

Merck

AHFS DI Essentials™. © Copyright 2021, Selected Revisions November 5, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

Show article references

Frequently asked questions